

F. No. 12(7)/2021/DP/NPPA/Div.III/ Vol-IV
National Pharmaceutical Pricing Authority

Subject: Minutes of the 45th meeting of the Multidisciplinary Committee of Experts held on 13.09.2022 at 02:00 PM.

45th meeting of the "Multidisciplinary Committee of Experts" was held on 13.09.2022 at 02.00 PM under the convenorship of Shri Manmohan Sachdeva, Advisor (Cost), through video-conferencing. The following members attended the meeting: -

1. Dr. J. J. Cherian, Scientist-D, ICMR through video conferencing
2. Dr. Rakesh Kr. Singh, Associate Professor, NIPER Raebareli through video conferencing
3. Dr. Jai Prakash, Sr. Principal Scientific Officer, Indian Pharmacopoea Commission – Co-opted member
4. Prof. Y. K. Gupta, Principal Scientific Advisor (projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi – Co-opted member
5. Dr. Pooja Gupta, Associate Professor, Department of Pharmacology, AIIMS- New Delhi

The following officers of NPPA attended and presented the cases before the Committee

1. Ms. Rashmi Tahiliani, Jt. Director (Pricing)
2. Shri Prasenjit Das, Deputy Director (Pricing), NPPA
3. Shri Mahaveer Saini, Deputy Director (Pricing), NPPA

1. Agenda No. 1 - Retail price fixation under Para 5 of DPCO, 2013 – Fixed Dose Combinations (FDCs) of Sitagliptin and Metformin tablet.

1.1 The Committee noted that twelve applications have been received for retail price fixation of six Fixed Dose Combinations (FDCs) of Sitagliptin and Metformin tablets i.e. (i) Sitagliptin 50 mg + Metformin 500 mg tablet, (ii) Sitagliptin 50 mg + Metformin 1000 mg tablet, (iii) Sitagliptin 50 mg + Metformin 1000 mg (extended release) tablet, (iv) Sitagliptin 50 mg + Metformin 500 mg (extended release) tablet (v) Sitagliptin 100 mg + Metformin 500 mg (extended release) tablet, (vi) Sitagliptin 100 mg + Metformin 1000 mg (extended release) tablet, The Committee further noted that the formulation 'Sitagliptin' has become off-patent on 5th/6th July 2022.

1.2. The Committee recalled the decision taken in its 40th meeting dated 14.03.2022 and approved by the Authority in its 96th meeting dated 24.03.2022 regarding retail price fixation of FDCs of 'Sitagliptin and Metformin tablet' in which the Authority decided as follows:

- (i) *The Authority noted that the formulation "Sitagliptin" has become/ is on the verge of becoming off-patent and observed that, in line with the decision taken in its 89th meeting dated 28.06.2021, if the calculation is based on six month*



prior market data, the price of the patented period would be taken into consideration and hence the price rationalisation due to expiry of the patent may not pass on to the patients.

(ii) The Authority further noted that matter was placed before the 40th meeting of the Multidisciplinary Committee of Experts held on 14.03.2022 which in line decision taken in the 89th Authority meeting dated 28.06.2021, recommended to fix the retail price as per the following methodology:

"...The Committee observed that the market data of the FDCs of Sitagliptin and Metformin tablet is also available and noted that if the retail price is calculated based on six month prior market data, the price of patented period would be taken into consideration and benefit of price reduction due to medicines which has become/ is on the verge of becoming off-patent would not pass not on to the consumers. The Committee deliberated upon the matter in detail and is of the opinion that the price of drugs be reduced in respect of the drugs which has become/ on the verge of becoming off-patent so as to pass the benefit of price reduction to the consumers and that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Sitagliptin' to arrive at the retail price. Accordingly, the Committee recommended to allow retail price for the FDCs of Sitagliptin and Metformin tablet in line with the decision taken in its 33rd meeting held on 21.06.2021. However, where the calculated retail price of the FDC of formulation based on six month prior market data as per the provisions of DPCO 2013 is lower than claimed price and the calculated price, the Committee recommended that the same would be allowed."

(iii) The Authority deliberated upon the matter in detail and accepted the recommendation of the Multidisciplinary Committee of Experts and approved the fixation of the price of new drugs as per the methodology stated by the Multidisciplinary Committee of Experts.

1.3 The Committee also noted the decision taken in its 41st, 42nd and 43rd meeting dated 08.04.2022, 02.06.2022 and 04.07.2022 is in line with the decision taken as mentioned Para 1.2 above and the same was approved by the Authority in its 97th meeting dated 06.05.2022, 99th meeting dated 28.06.2022 and 100th meeting dated 05.08.2022 regarding retail price fixation of FDCs of 'Sitagliptin and Metformin tablet'. The Committee also noted that it also recommended the retail price of FDCs of 'Sitagliptin+ Metformin' tablet as per the methodology mentioned in Para 1.2 in its 44th meeting dated 04.08.2022. The Committee observed that the market data of the FDCs of Sitagliptin and Metformin tablet is also available in some cases and noted that if the retail price is calculated based on six month prior market data, the price of patented period would be taken into consideration and benefit of price reduction due to medicines which has become would not pass on to the consumers. The Committee deliberated upon the matter in detail and is of the opinion that the price of drugs be reduced in respect of the drugs which has become off-patent so as to pass the benefit of price reduction to the consumers on account of the drug becoming off-patented. The Committee therefore recommended that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Sitagliptin' to arrive at the retail price for the FDCs of Sitagliptin and Metformin tablet in line with the decision taken in its 41st, 42nd and 43rd meeting held on 08.04.2022, 02.06.2022 and 04.07.2022 and the same were approved by the Authority in its 97th, 99th and 100th meeting held on 06.05.2022, 02.06.2022 and 04.07.2022.



1.4 Accordingly, the Committee recommended the retail price of FDCs of Sitagliptin + Metformin Hydrochloride IP tablet for various companies as detailed below:

1.4.1 Each film coated bilayered tablet containing Sitagliptin Phosphate 62.03 mg eq. to Sitagliptin 50 mg + Metformin Hydrochloride USP/Ph. Eur 1000 mg (as Extended Release) for M/s MSN Laboratories Pvt. Limited (manufacturer and marketer) at Rs. 9.73 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated tablet containing Sitagliptin Phosphate 62.03 mg eq. to Sitagliptin 50 mg + Metformin Hydrochloride USP/Ph. Eur 1000 mg (as Extended Release)		
(a)	Derived retail price of Sitagliptin 50 mg tablet	Retail price (as per January, 2022 data)	34.27
(b)	50% of (a)		17.13
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.66
(d)	Retail Price		20.79
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.73
(f)	Worked out Retail Price (d)-(e)		20.06
(g)	Claimed Retail price		09.73
(h)	Retail price of FDC of 'Sitagliptin 50mg + Metformin 1000mg (ER) tablet' as per Pharmatrac Data for January, 2022		NA
(i)	Recommended retail price		9.73

1.4.2 Each film coated bilayered tablet containing Sitagliptin Phosphate 124.06 mg eq. to Sitagliptin 100 mg + Metformin Hydrochloride USP/Ph. Eur 1000 mg (as Extended Release) for M/s MSN Laboratories Pvt. Limited (manufacturer and marketer) at Rs. 14.19 per tablet excluding GST as detailed below:

S. No.	Particulars	Source / Method	Amount (Rs.)
--------	-------------	-----------------	--------------

Q

S. No.	Particulars	Source / Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate 124.06 mg eq. to Sitagliptin 100 mg + Metformin Hydrochloride USP/Ph. Eur 1000 mg (as Extended Release)		
(a)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per January, 2022 data)	37.27
(b)	50% of (a)		18.63
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.66
(d)	Retail Price		22.29
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.73
(f)	Worked out Retail Price (d)-(e)		21.56
(g)	Claimed Retail price		14.19
(h)	Retail price of FDC of 'Sitagliptin 100mg + Metformin 1000mg (ER) tablet' as per Pharmatrac Data for January, 2022		NA
(i)	Recommended retail price		14.19

1.4.3 Each film coated bilayered tablet containing Sitagliptin Phosphate 62.03 mg eq. to Sitagliptin 50 mg + Metformin Hydrochloride USP/Ph. Eur 500 mg (as Extended Release) for M/s MSN Laboratories Pvt. Limited (manufacturer and marketer) at Rs. 9.28 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate 62.03 mg eq. to Sitagliptin 50 mg + Metformin Hydrochloride USP/Ph. Eur 500 mg (as Extended Release)		
(a)	Derived retail price of Sitagliptin 50 mg tablet	Retail price (as per January, 2022 data)	34.27
(b)	50% of (a)		17.13

R

S. No.	Particulars	Source/Method	Amount (Rs.)
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	1.92
(d)	Retail Price		19.05
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.38
(f)	Worked out Retail Price (d)-(e)		18.67
(g)	Claimed Retail price		09.28
(h)	Retail price of FDC of 'Sitagliptin 50mg + Metformin 500mg (ER) tablet" as per Pharmatrac Data for January, 2022		NA
(i)	Recommended retail price		9.28

1.4.4 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (As Extended Release Form) for M/s Exemed Pharmaceuticals (manufacturer) and M/s Sun Pharma Laboratories Limited (marketer) at Rs. 20.17 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as Extended Release form)		
(a)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per January, 2022 data)	37.27
(b)	50% of (a)		18.63
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	1.92
(d)	Retail Price		20.55
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen		0.38

f

S. No.	Particulars	Source/Method	Amount (Rs.)
	Committee report		
(f)	Worked out Retail Price (d)-(e)		20.17
(g)	Claimed Retail price		22.32
(h)	Retail price of FDC of 'Sitagliptin 100mg + Metformin 500mg (ER) tablet" as per Pharmatrac Data for January, 2022		NA
(i)	Recommended retail price		20.17

1.4.5 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended-Release Form) for M/s Exemed Pharmaceuticals (Manufacturer) and M/s Macleods Pharmaceuticals Limited (Marketer) at Rs. 21.56 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release Form)		
(a)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per January, 2022 data)	37.27
(b)	50% of (a)		18.63
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.66
(d)	Retail Price		22.29
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.732
(f)	Worked out Retail Price (d)-(e)		21.56
(g)	Claimed Retail price		26.78
(h)	Retail price of FDC of 'Sitagliptin 100mg + Metformin 1000mg (ER) tablet" as per Pharmatrac Data for January, 2022		NA

92

S. No.	Particulars	Source/Method	Amount (Rs.)
(i)	Recommended retail price		21.56

1.4.6 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 1000 mg (as Extended-Release Form) for M/s Exemed Pharmaceuticals (Manufacturer) and M/s Macleods Pharmaceuticals Limited (Marketer) at Rs. 20.06 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release Form)		
(a)	Derived retail price of Sitagliptin 50 mg tablet	Retail price (as per January, 2022 data)	34.27
(b)	50% of (a)		17.13
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.66
(d)	Retail Price		20.79
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.73
(f)	Worked out Retail Price (d)-(e)		20.06
(g)	Claimed Retail price		25.89
(h)	Retail price of FDC of 'Sitagliptin 50mg + Metformin 1000mg (ER) tablet' as per Pharmatrac Data for January, 2022		NA
(i)	Recommended retail price		20.06

1.4.7 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as Extended Release Form) for M/s Exemed Pharmaceuticals (Manufacturer) and M/s Macleods Pharmaceuticals Limited (Marketer) at Rs. 20.17 per tablet excluding GST as detailed below:

Pz

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as Extended Release Form)		
(a)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per January, 2022 data)	37.27
(b)	50% of (a)		18.63
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	1.92
(d)	Retail Price		20.55
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.38
(f)	Worked out Retail Price (d)-(e)		20.17
(g)	Claimed Retail price		25.89
(h)	Retail price of FDC of 'Sitagliptin 100mg + Metformin 500mg (ER) tablet' as per Pharmatrac Data for January, 2022		NA
(i)	Recommended retail price		20.17

1.4.8 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg (as Extended-Release Form) for M/s Exemed Pharmaceuticals (Manufacturer) and M/s Macleods Pharmaceuticals Limited (Marketer) at Rs. 18.67 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg (as Extended Release Form)		
(a)	Derived retail price of Sitagliptin 50 mg tablet	Retail price (as per January, 2022 data)	34.27



S. No.	Particulars	Source/Method	Amount (Rs.)
(b)	50% of (a)		17.13
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	1.92
(d)	Retail Price		19.05
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.384
(f)	Worked out Retail Price (d)-(e)		18.67
(g)	Claimed Retail price		22.32
(h)	Retail price of FDC of 'Sitagliptin 50mg + Metformin 500mg (ER) tablet" as per Pharmatrac Data for January, 2022		NA
(i)	Recommended retail price		18.67

1.4.9 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 1000 mg for M/s Macleods Pharmaceuticals Limited (Manufacturer and Marketer) at Rs. 20.02 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 1000 mg		
(a)	Derived retail price of Sitagliptin 50 mg tablet	Retail price (as per January, 2022 data)	34.27
(b)	50% of (a)		17.13
(c)	Metformin IR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.61
(d)	Retail Price		20.74
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.722

9

S. No.	Particulars	Source/Method	Amount (Rs.)
(f)	Worked out Retail Price (d)-(e)		20.02
(g)	Claimed Retail price		25.89
(h)	Retail price of FDC of 'Sitagliptin 50mg + Metformin 1000mg tablet" as per Pharmatrac Data for January, 2022		22.97
(i)	Recommended retail price		20.02

1.4.10 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg for M/s Macleods Pharmaceuticals Limited (Manufacturer and Marketer) at Rs. 18.34 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg		
(a)	Derived retail price of Sitagliptin 50 mg tablet	Retail price (as per January, 2022 data)	34.27
(b)	50% of (a)		17.13
(c)	Metformin IR 500 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	1.51
(d)	Retail Price		18.64
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.30
(f)	Worked out Retail Price (d)-(e)		18.34
(g)	Claimed Retail price		22.32
(h)	Retail price of FDC of 'Sitagliptin 50mg + Metformin 500mg tablet" as per Pharmatrac Data for January, 2022		22.39
(i)	Recommended retail price		18.34

q

1.4.11 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as Extended-Release Form) for M/s Theon Pharmaceuticals Limited (Manufacturer) and M/s Wockhardt Limited (Marketer) at Rs. 11.60 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as Extended-Release Form)		
(a)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per January, 2022 data)	37.27
(b)	50% of (a)		18.63
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	1.92
(d)	Retail Price		20.55
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.384
(f)	Worked out Retail Price (d)-(e)		20.17
(g)	Claimed Retail price		11.60
(h)	Retail price of FDC of 'Sitagliptin 100mg + Metformin 500mg (ER) tablet' as per Pharmatrac Data for January, 2022		NA
(i)	Recommended retail price		11.60

1.4.12 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release Form) for M/s Theon Pharmaceuticals Limited (Manufacturer) and M/s Wockhardt Limited (Marketer) at Rs. 12.50 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as		

h

S. No.	Particulars	Source/Method	Amount (Rs.)
	Extended Release Form)		
(a)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per January, 2022 data)	37.27
(b)	50% of (a)		18.63
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.66
(d)	Retail Price		22.29
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.73
(f)	Worked out Retail Price (d)-(e)		21.56
(g)	Claimed Retail price		12.50
(h)	Retail price of FDC of 'Sitagliptin 100mg + Metformin 1000mg (ER) tablet' as per Pharmatrac Data for January, 2022		NA
(i)	Recommended retail price		12.50

2. Agenda No. 2 - Application by M/s AxaParenterals Ltd. for separate price under Para 11(3) of DPCO 2013 with respect to (i) Dextrose Injection 25%w/v in 100 ml pack in Non-glass with special feature for in LDPE container with Euro Head (ii) Mannitol injection 20 gm per 100ml in 100 ml pack in Non-glass with special feature for in LDPE container with Euro Head (iii) Metronidazole Injection IP 500mg/100ml in 100ml 100 ml pack in Non-glass with special feature for in LDPE container with Euro Head.

2.1 The Committee noted the request made by M/s Axa Parenterals Ltd vide e-mail dated 10.09.2022 for withdrawal of the applications. The Committee deliberated upon the matter in detail and decided to close the application made by M/s AxaParenterals Ltd. for separate price under Para 11(3) of DPCO 2013 with respect to (i) Dextrose Injection 25%w/v in 100 ml pack in Non-glass with special feature for in LDPE container with Euro Head (ii) Mannitol injection 20 gm per 100ml in 100 ml pack in Non-glass with special feature for in LDPE container with Euro Head (iii) Metronidazole Injection IP 500mg/100ml in 100ml 100 ml pack in Non-glass with special feature for in LDPE container with Euro Head based on the request of the company as requested by the company.

Ar

3. Agenda No. 3 - Application by M/s AxaParenterals Ltd. for separate price for Non-Glass with special feature for (i) Ciprofloxacin Injection IP, Compound Sodium lactate Injection IP (Ringer Lactate Solution for injection IP), Dextrose Injection IP (10% w/v), Dextrose Injection (5% w/v) and Fluconazole Injection USP 100 ml in LDPE container with Euro Head.

3.1 The Committee noted the request made by M/s Axa Parenterals Ltd vide e-mail dated 10.09.2022 for withdrawal of the applications. The Committee deliberated upon the matter in detail and decided to close the application made by M/s Axa Parenterals Ltd. for separate price for Non-Glass with special feature for (i) Ciprofloxacin Injection IP, Compound Sodium lactate Injection IP (Ringer Lactate Solution for injection IP), Dextrose Injection IP (10% w/v), Dextrose Injection (5% w/v) and Fluconazole Injection USP 100 ml in LDPE container with Euro Head as requested by the company

4. Agenda No. 4 - Application for extension of ceiling price of Sodium Chloride Injection 0.9% in 500 ml with packaging in non glass with special feature in line with S.O.1500(E) dated 30.03.2022.

4.1 The Committee noted the documents submitted by M/s Puerto Life Sciences Pvt. Ltd and the demonstration made by the company. The Committee observed that the entire fluid of the bottle gets drained out due to self-collapsibility. Though there is relatively slow out flow at the fag end of the bottle but it will not effect in treatment as in practice, the flowrate is monitored by the regulator. The company has also provided the leaching data from the NABL accredited laboratory.

4.2 The Committee deliberated upon the matter in detail and decided to extend the ceiling prices and the formulations mentioned in SO. 1500(E) dated 30.03.2022 to M/s Puerto Life Sciences Pvt. Ltd for the formulation 'Sodium Chloride Injection 0.9% in 500 ml with packaging in non glass with special feature.

5. Agenda No. 5 - Application for extension of ceiling price of (i) Glucose Injection 5% in 500ml Non Glass With special features with Euro Head and (ii) Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) in 500ml Non Glass With special features with Euro Head in line with S.O.1500(E) dated 30.03.2022.

5.1 The Committee noted the documents submitted by M/s Puerto Life Sciences Pvt. Ltd and the demonstration made by the company. The Committee observed that the entire fluid of the bottle gets drained out due to self-collapsibility. Though there is relatively slow out flow at the fag end of the bottle but it will not effect in treatment as in practice, the flowrate is monitored by the regulator. The company has also provided the leaching data from the NABL accredited laboratory.

5.2 The Committee deliberated upon the matter in detail and decided to extend the ceiling prices and the formulations mentioned in SO. 1500(E) dated 30.03.2022 to M/s Puerto Life Sciences Pvt. Ltd for the formulations (i) Glucose Injection 5% in 500ml Non Glass With special features with Euro Head and (ii) Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) in 500ml Non Glass With special features with Euro Head.

6. Agenda No. 6 – Application for extension of ceiling price of Ringer lactate injection with packaging in non glass with special feature in line with S.O. 1501(E) dated 30.03.2022.

6.1 The Committee noted the documents submitted by M/s Puerto Life Sciences Pvt. Ltd and the demonstration made by the company. The Committee observed that the entire fluid of the bottle gets drained out due to self-collapsibility. Though there is relatively slow out flow at the fag end of the bottle but it will not effect in treatment as in practice, the flowrate is monitored by the regulator. The company has also provided the leaching data from the NABL accredited laboratory.

6.2 The Committee deliberated upon the matter in detail and decided to extend the ceiling prices and the formulations mentioned in SO. 1501(E) dated 30.03.2022 to M/s Puerto Life Sciences Pvt. Ltd for the formulation Ringer lactate injection in 500 ml pack with packaging in non glass with special feature.

7. Agenda No. 7: Approval for ceiling price of different dosage forms and strength of I.V Fluids with packaging in non glass with special features "SAFE PORT" dated 09.05.2022 being filed by M/s Sachin Parenteral Pvt. Ltd.

7.1 The Committee noted the documents submitted by M/s Sachin Parenteral Pvt. Ltd and the demonstration made by the company. The Committee observed that there is no major variation in the flowrate in beginning and end which may interfere with the therapy and the entire fluid of the bottle gets drained out due to self-collapsibility. The Committee further noted that in treatment as in practice, the flowrate is monitored by the regulator. The company has also provided the data related to leaching and the committee observed that leaching is negative

7.2 The Committee deliberated upon the matter in detail and decided to extend the ceiling prices and the formulations mentioned in SO. 1500(E) dated 30.03.2022 to M/s Sachin Parenteral Pvt. Ltd for the formulations (i) Dextrose(Glucose) Injection 5% w/v in 500 ml pack with packaging in non glass with special features with brand 'safe port' (ii) Sodium Chloride Injection 0.9% w/v in 100 ml pack with packaging in non glass with special features with brand 'safe port' (iii) Sodium Chloride Injection 0.9% w/v in 250 ml pack with packaging in non glass with special features with brand 'safe port' (iv) Sodium Chloride Injection 0.9% w/v in 500 ml pack with packaging in non glass with special features with brand 'safe port' (v) Glucose 5% + Sodium Chloride 0.9 % Injection m/v in 500 ml pack with packaging in non glass with special features with brand 'safe port'. The Committee also decided to extend the ceiling prices and the formulations mentioned in SO. 1501(E) dated 30.03.2022 to M/s Sachin Parenteral Pvt. Ltd for the formulations Ringer lactate injection in 500 ml pack with packaging in non glass with special feature with brand 'safe port'

8. Agenda No. 8: Application for Price approval of Dextrose Injection IP (5% w/v) 250ml, Dextrose Injection IP (25% w/v) in 100ml, Glucose 5% with sodium chloride 0.9% w/v 250ml, Metronidazole Injection IP 100ml, Mannitol Injection IP (20% w/v) 100ml non-glass having special features- Euro Head bottle dated. 16.05.2022.

8.1 The Committee noted the documents submitted by M/s Sachin Parenteral Pvt. Ltd and the demonstration made by the company. The Committee observed that there is no major variation in the flowrate in beginning and end which may interfere with the therapy and the entire fluid of the bottle gets drained out due to self-collapsibility. The Committee further noted that in treatment as in practice, the flowrate is monitored by the regulator. The company has also provided the data related to leaching and the committee observed that leaching is negative.

8.2 The Committee deliberated upon the matter in detail and decided to extend to M/s Sachin Parenteral Pvt. Ltd, the ceiling prices and the formulations mentioned in (i) SO. 1504(E) dated 30.03.2022 for the formulation Metronidazole Injection (0.5%w/v) 500mg/100ml in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features, (ii) SO. 1505(E) dated 30.03.2022 for the formulation Mannitol Injection 20% in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features and (iii) SO. 1506(E) dated 30.03.2022 for the formulation Dextrose (Glucose) Injection (25%w/v) in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features.

8.3 The Committee further noted that the separate ceiling price of the formulation (i) Dextrose (Glucose) Injection 5% w/v in 250 ml pack with packages in non glass pack having special features and (ii) Glucose 5% + Sodium Chloride 0.9 % Injection w/v in 250 ml pack with packaging in non glass with special feature has not been fixed earlier. The Committee deliberated upon the matter in details and decided to provide the separate ceiling price for these formulations by allowing 15 percent over the present applicable ceiling price of the formulations (i) Glucose Injection % in 250 ml non-glass pack and (ii) Glucose 5% + Sodium Chloride 0.9 % Injection in 250 ml non-glass pack respectively. Accordingly, the Committee decided to provide the separate ceiling price to M/s Sachin Parenterals Pvt. Ltd for the formulations (i) Dextrose (Glucose) Injection 5% w/v in 250 ml pack with packages in non glass pack having special features at Rs. 28.74 per pack excluding GST and (ii) Glucose 5% + Sodium Chloride 0.9 % Injection w/v in 250 ml pack with packaging in non glass with special feature at Rs. 28.84 per pack excluding GST, under para 11(3) of DPCO 2013, as detailed below, based on the demonstration by the company:

(i) Separate ceiling price of Dextrose (Glucose) Injection 5% w/v in 250 ml pack with packages in non glass pack having special features

(a) Present applicable ceiling price of Glucose Injection % in 250 ml non-glass pack = Rs. 24.99 per pack excluding GST [SO. 1499(E) dated 30.03.2022]

Therefore, separate ceiling price of Dextrose (Glucose) Injection 5% w/v in 250 ml pack with packages in non glass pack having special features after allowing 15% increase over 8.3(i)(a) above = Rs. 28.74 per pack excluding GST. [Rs. 24.99 X 1.15]

(ii) Separate ceiling price of Glucose 5% + Sodium Chloride 0.9 % Injection w/v in 250 ml pack with packaging in non glass with special feature

(a) Present applicable ceiling price of Glucose 5% + Sodium Chloride 0.9 % Injection in 250 ml non-glass pack = Rs. 25.08 per pack excluding GST [SO. 1499(E) dated 30.03.2022]

Therefore, separate ceiling price of Glucose 5% + Sodium Chloride 0.9 % Injection in 250 ml pack with packages in non glass pack having special features after allowing 15% increase over 8.3(ii)(a) above = Rs. 28.84 per pack excluding GST.[Rs. 25.08X1.15]

9. Agenda No. 9: Application for "Special Feature rate" for scheduled products (i) Tazofic Injection 2.25 gm containing Piperacillin 2gm+Tazobactam 250mg and (ii) Tazofic Injection 4.5 gm containing Piperacillin 4gm+Tazobactam 500 mg under Para 11(3) of DPCO 2013.

9.1 The Committee noted the documents submitted by M/s Gufic Biosciences Ltd and the demonstration made by the company. The Committee observed that the dual chamber bag will help in reconstitution of the drug with distilled water with reduction in the possibility of contamination. The Committee deliberated upon the matter in detail and decided to provide addition 15 percent price over the present applicable ceiling price of the formulation for incremental innovation of the packaging. Accordingly, the Committee decided to provide the ceiling price of (i) Tazofic Injection 2.25 gm containing Piperacillin 2gm+Tazobactam 250mg at Rs. 267.03 per pack excluding GST and (ii) Tazofic Injection 4.5 gm containing Piperacillin 4gm+Tazobactam 500 mg at Rs. 560.92 per pack excluding GST under para 11(3) of DPCO 2013 as detailed below:

Sl. No.	Medicine	Dosage form and strength	Unit	Ceiling price (excluding GST) as per SO. 1499(E) dated 30.03.2022	Recommended ceiling price under Para 11(3) of DPCO 2013 [(e) X 1.15]
(a)	(b)	(c)	(d)	(e)	(f)
1	Piperacillin (A) + Tazobactam (B)	Powder for Injection 2 g (A) + 250 mg(B)	Each pack	Rs. 232.20	Rs. 267.03
2	Piperacillin (A) + Tazobactam (B)	Powder for Injection 4 g (A) + 500 mg(B)	Each pack	Rs. 487.76	Rs. 560.92

10. Agenda No. 10: Retail price fixation under Para 5 of DPCO, 2013- Each Sachet Contains: Pantoprazole Sodium Eq. to Pantoprazole 40mg (Sodium Bicarbonate as buffer) for M/s Alkem Laboratories Ltd. (Manufacturer & Marketer)

10.1 The Committee noted the application of M/s Alkem Laboratories Ltd for retail price fixation of each Sachet containing Pantoprazole Sodium Eq. to Pantoprazole 40mg (Sodium Bicarbonate as buffer) and observed that Pantoprazole 40 mg tablet is available in the market and its calculated retail price based on November 2021 data comes to Rs. 7.30 per tablet excluding GST. The Committee deliberated upon the matter in detail and is of the opinion that there is negligible variation in the route

Pr

of administration between tablet and sachet and both the dosage type be considered as similar and decided to extend the price of tablet to sachet. Accordingly, the Committee recommended the retail price of each Sachet containing Pantoprazole Sodium Eq. to Pantoprazole 40mg (Sodium Bicarbonate as buffer) for M/s Alkem Laboratories Ltd. (Manufacturer & Marketer) at Rs 7.30 per sachet excluding GST.

11. Agenda No. 11: Retail price fixation under Para 5 of DPCO, 2013- Ibuprofen solution for infusion in which each 100ml contains Ibuprofen 400mg for M/s Akums Drugs & Pharmaceuticals Limited (Manufacturer) and M/s Cipla Ltd. (Marketer)

11.1 The Committee deliberated upon the matter in detail and recommended the retail price of Ibuprofen solution for infusion in which each 100ml contains Ibuprofen 400mg for M/s Akums Drugs & Pharmaceuticals Limited (Manufacturer) and M/s Cipla Ltd. (Marketer) at Rs122.19 per 100 ml pack excluding GST (being lower than the price claimed by the company at Rs. 579.46 per 100 ml pack excluding GST) as detailed below:

i. The formulation "Ibuprofen" and "Paracetamol" are in the similar therapeutic category and accordingly the retail price of ibuprofen infusion is calculated based on the equivalent pricing structure/ drug contents/ dosage type and strength of paracetamol.

ii. Paracetamol

(a) Ceiling price of Paracetamol 650 mg tablet as on December 2021 = Rs. 1.84 per tablet excluding GST [SO. 1330(E) dated 25.03.2021]

(b) Derived price of Paracetamol 1000 mg tablet after applying the formula of Pronab Sen Committee on the price as per (b) above

$$P(s) = P^* \cdot [1 + a \cdot \{(s - s^*) / s^*\}]$$

Where: P(s) = Price ceiling of the strength s

P* = price ceiling for reference strength s*

s = strength in terms of API content

s* = reference strength

a = 0.8 for tablet / capsule and 0.7 for injectibles.

$$= 1.84[1 + 0.80\{(1000 - 650) / 650\}] = \text{Rs. 2.63 per tablet excluding GST}$$

(c) Calculated retail price of Paracetamol 1000mg/100ml infusion based on December 2021 data [Pharmatrac database July 2022] = Rs. 309.00 per 100 ml pack

(d) Ratio of (c) to (b) = $309/2.63 = 117.49$ [this is the ratio of Paracetamol 1000mg/100 ml infusion per pack to the derived price of Paracetamol 1000 mg tablet]

(iii) Ibuprofen

(a) Ceiling price of Ibuprofen 400 mg tablet as on December 2021 = Rs. 1.04 per tablet excluding GST [SO. 2654(E) dated 01.07.2021]

(b) Applying the derived ratio as specified in 11(ii)(d) to the price of ceiling price of Ibuprofen 400 mg tablet as specified in 11(iii)(a), it comes to Rs. 122.19 [Rs. 1.04 X 117.49]

(c) The price as derived i.e. Rs. 122.19 may be taken as Ibuprofen 400mg/100ml infusion in 100 ml pack, in line with the rational as specified above.

12. Agenda No. 12 - Retail price fixation under Para 5 of DPCO, 2013- Each Adhesive Patch contains "Lidocaine 700mg in an aqueous base (50mg per gm adhesive) for M/s Hetero Healthcare Limited (Manufacturer and Marketer)

12.1 The Committee deliberated upon the matter in detail and recommended the retail price of each Adhesive Patch containing "Lidocaine 700mg in an aqueous base (50mg per gm adhesive) for M/s Hetero Healthcare Limited (Manufacturer and Marketer) at Rs9.94 per patch excluding GST (being lower than the price claimed by the company at Rs. 44.64 per patch excluding GST) as detailed below:

i. The formulation "Lidocaine" and "Fentanyl" are in the similar therapeutic category and accordingly the retail price of lidocaine patch is calculated based on the equivalent pricing structure/ drug contents/ dosage type and strength of Fentanyl.

ii. Fentanyl

a. Applicable Ceiling price of Fentanyl Injection 50mcg/ml as on November 2021 = Rs. 22.76 per ml excluding GST [SO. 1330(E) dated 25.03.2021]

b. Calculated price of Fentanyl 4.2 mg transdermal patch base on November 2021 data [Pharmatrac database July 2022] = Rs. 549.06 per patch excluding GST. The transdermal patch contains Fentanyl 4.2 mg i.e. 4200 mcg.

c. Derived retail price of Fentanyl 50mcg transdermal patch as per unitary method on the price as per (b) above

= Rs, $549.06 \times 50 / 4200 =$ Rs. 6.53 per pack excluding GST

d. Ratio of (c) to (a) = $6.53 / 22.76 = 0.28691$ [this is the ratio of derived price of Fentanyl 50mcg patch to the ceiling price of Fentanyl 50mcg/ml injection].

iii. Lignocaine (Lidocaine)

a. Applicable ceiling price of Lignocaine (Lidocaine) Injection 2% (Lignocaine i.e 20mg per ml) as on November 2021 = Rs. 0.99 per ml excluding GST [SO. 1330(E)

dated 25.03.2021]. Therefore, derived price of Lignocaine Injection containing absolute lignocaine 700 mg = $\text{Rs. } 0.99 \times 700 / 20 = \text{Rs. } 34.65$.

b. Applying the derived ratio as specified in 12(ii)(d) to the derived price of Lignocaine injection containing Lignocaine 700 mg as specified in 12(iii)(a), it comes to Rs. 9.94 [Rs. 34.65×0.28691]

c. The price as derived as per 12(iii)(b) i.e. Rs. 9.94 may be taken as Lignocaine 700 mg patch, in line with the rational as specified above.

The meeting ended with a vote of thanks to all.

Copy to:
All members of the Committee.

Rashmi
14/9/2022
(Rashmi Tahiliani)
Jt. Director (Pricing)

Computation of Retail Price based on November, 2021 Data under Para 5 of DPCO, 2013

Each tablet containing Pantoprazole 40 mg

Number of Companies consisting of Market Share of 1% & Above					6
Sum of MAT value considered for price calculation (In Lakhs)					76,784.82
Sum of PTR per unit considered for price calculation					37.73
Number of Packs considered					6
Average PTR					6.29
Add : 16% Retailer Margin					1.01
Retail Price (without local taxes)					7.30
% Reduction with compared to Highest Price					33.37%

Minimum Price (Rs.)				2.76
Maximum Price (Rs.)				9.44
Average of all considered (Rs.)				6.29
Retail Price (Rs.)				7.3

S.No.	पैक विवरण Pack Description	ब्रांड BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	8,47,52,07,916	100%	M3				
								MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered	
1	ACIBAN 40 MG TABLET 10	ACIBAN	CADILA PHARMACEUTICALS LTD	40 MG	10	TABLET	52.21	10690755	0.13%	0.13%	N	5.22		
2	ACILLECT 40 MG TABLET 10	ACILLECT	INTELLECT LIFESCIENCE	40 MG	10	TABLET	34.13		68	0.00%	0.00%	N	3.41	
3	ACIPAN 40 MG TABLET 10	ACIPAN	PANZER PHARMACEUTICALS PVT LTD	40 MG	10	TABLET	95.72	400929	0.00%	0.00%	N	9.57		
4	ACIPANT (BSP) 40 MG TABLET 10	ACIPANT (BSP)	BSP PHARMACEUTICALS	40 MG	10	TABLET	39.29	25226	0.00%	0.00%	N	3.93		
5	ACIPANT DM(BSP) 40 MG TABLET 10	ACIPANT DM(BSP)	BSP PHARMACEUTICALS	40 MG	10	TABLET	27.36	65172	0.00%	0.00%	N	2.74		
6	ACIPENT 40 MG TABLET 10	ACIPENT	FRANKLIN LABORATORIES (INDIA) PVT. LTD.	40 MG	10	TABLET	22.14	7683	0.00%	0.00%	N	2.21		
7	ADPAN 40 MG TABLET 10	ADPAN	ADVENT LIFE SCIENCES PVT LTD	40 MG	10	TABLET	64.31	1765	0.00%	0.00%	N	6.43		
8	ALDEPRAZ 40 MG TABLET 10	ALDEPRAZ	ALDE MEDI IMPEX	40 MG	10	TABLET	41.43	99266	0.00%	0.00%	N	4.14		
9	ALENTRA 40 MG TABLET 10	ALENTRA	AURUM LIFE SCIENCE PVT. LTD.	40 MG	10	TABLET	51.75	551	0.00%	0.00%	N	5.18		
10	ANLEO 40 MG TABLET 10	ANLEO	AN PHARMACEUTICALS PVT.LTD.	40 MG	10	TABLET	62.86	996520	0.01%	0.01%	N	6.29		
11	APENTA 40 MG TABLET 10	APENTA	STARTOS HEALTH CARE PVT.LTD	40 MG	10	TABLET	49.29	9071	0.00%	0.00%	N	4.93		
12	APNICID 40 MG TABLET 10	APNICID	AJANTA PHARMA LTD	40 MG	10	TABLET	12.00	60513	0.00%	0.00%	N	1.20		
13	ARLOC 40 MG TABLET 10	ARLOC	DR. JOHNS LABORATORIES PVT LTD	40 MG	10	TABLET	58.93	243322	0.00%	0.00%	N	5.89		
14	ASSUAG 40 MG TABLET 10	ASSUAG	UMANO HEALTHCARE PVT.LIMITED	40 MG	10	TABLET	51.79	122328	0.00%	0.00%	N	5.18		
15	ATCID 40 MG TABLET 10	ATCID	ATOPIC LABORATORIES	40 MG	10	TABLET	31.43	2183379	0.03%	0.03%	N	3.14		
16	AUXITOP 40 MG TABLET 10	AUXITOP	ALNICHE LIFE SCIENCES PVT.LTD	40 MG	10	TABLET	72.86	14863	0.00%	0.00%	N	7.29		
17	AUXITOP 40 MG TABLET 15	AUXITOP	ALNICHE LIFE SCIENCES PVT.LTD	40 MG	15	TABLET	108.57	35285	0.00%	0.00%	N	7.24		
18	BEEP 40 MG TABLET 10	BEEP	HAMPS INDIA PVT LTD	40 MG	10	TABLET	41.43	160210	0.00%	0.00%	N	4.14		
19	CNPRAZ 40 MG TABLET 10	CNPRAZ	CNX HEALTHCARE PVT LTD	40 MG	10	TABLET	57.86	2325162	0.03%	0.03%	N	5.79		
20	COCID 40 MG TABLET 10	COCID	TALENT INDIA	40 MG	10	TABLET	57.14	2564500	0.03%	0.03%	N	5.71		
21	COCID 40 MG TABLET 14	COCID	TALENT INDIA	40 MG	14	TABLET	14.77	269892	0.00%	0.00%	N	1.06		
22	CONTROSEC 40 MG TABLET 10	CONTROSEC	EMBIOTIC LAB	40 MG	10	TABLET	54.64	139142	0.00%	0.00%	N	5.46		
23	CUREPAN 40 MG TABLET 10	CUREPAN	DR. CURE PHARMACEUTICAL	40 MG	10	TABLET	37.50	1097475	0.01%	0.01%	N	3.75		
24	DALGUT 40 MG TABLET 10	DALGUT	PHOENIX LIFESCIENCES	40 MG	10	TABLET	42.86	79677	0.00%	0.00%	N	4.29		
25	DEUZOLE 40 MG TABLET 10	DEUZOLE	TENET HEALTHCARE	40 MG	10	TABLET	46.72	56998	0.00%	0.00%	N	4.67		
26	DIGENE-TOTAL 40 MG TABLET 10	DIGENE-TOTAL	ABBOTT INDIA LTD.	40 MG	10	TABLET	77.76	7620	0.00%	0.00%	N	7.78		
27	DIPENT DM 40 MG TABLET 10	DIPENT DM	DIVINE LIFECARE PVT LTD	40 MG	10	TABLET	40.36	412653	0.00%	0.00%	N	4.04		
28	DOCTOR PAN 40 MG TABLET 15	DOCTOR PAN	DR. REDDYS LABORATORIES LTD	40 MG	15	TABLET	113.57	5512234	0.07%	0.07%	N	7.57		
29	DONAZOL 40 MG TABLET 10	DONAZOL	MEDOZ PHARMA	40 MG	10	TABLET	48.75	87311	0.00%	0.00%	N	4.88		
30	DUOPEP 40 MG TABLET 10	DUOPEP	APEX LABORATORIES LTD.	40 MG	10	TABLET	50.00	5010650	0.06%	0.06%	N	5.00		
31	DYCIZOL 40 MG TABLET 10	DYCIZOL	DYCINE PHARMACEUTICALS	40 MG	10	TABLET	64.29	2991092	0.04%	0.04%	N	6.43		
32	DYSPAN 40 MG TABLET 10	DYSPAN	GRACIOUS PHARMACEUTICALS	40 MG	10	TABLET	54.00	115506	0.00%	0.00%	N	5.40		
33	EC PAN 40 MG TABLET 10	EC PAN	ICON LIFESCIENCES	40 MG	10	TABLET	51.43	2475873	0.03%	0.03%	N	5.14		
34	ELESEC 40 MG TABLET 10	ELESEC	CANVARZYS PHARMACEUTICALS	40 MG	10	TABLET	49.36	395	0.00%	0.00%	N	4.94		
35	ERACID 40 MG TABLET 10	ERACID	MANEESH PHARMACEUTICALS LTD	40 MG	10	TABLET	45.36	62959	0.00%	0.00%	N	4.54		
36	FLORITEX 40 MG TABLET 10	FLORITEX	MAYFLOWER INDIA	40 MG	10	TABLET	16.80	62210	0.00%	0.00%	N	1.68		
37	FORPAN 40 MG TABLET 10	FORPAN	FORGEN HEALTHCARE LTD.	40 MG	10	TABLET	69.14	113113	0.00%	0.00%	N	6.91		
38	FRIOPAN 40 MG TABLET 10	FRIOPAN	ARINNA LIFESCIENCES PVT. LTD	40 MG	10	TABLET	50.45	553386	0.01%	0.01%	N	5.05		
39	FUPAN 40 MG TABLET 10	FUPAN	FUSION HEALTHCARE PVT LTD	40 MG	10	TABLET	49.29	1962876	0.02%	0.02%	N	4.93		
40	GASTROPAN 40 MG TABLET 10	GASTROPAN	KIVI LABS LTD	40 MG	10	TABLET	56.43	217477	0.00%	0.00%	N	5.64		
41	GEPAN 40 MG TABLET 10	GEPAN	GUFIC BIOSCIENCE LTD	40 MG	10	TABLET	42.79	17702	0.00%	0.00%	N	4.28		
42	GERIPAN 40 MG TABLET 10	GERIPAN	GERRY SUN PHARMACEUTICALS PVT.LTD	40 MG	10	TABLET	50.00	122415	0.00%	0.00%	N	5.00		
43	GIPANT 40 MG TABLET 10	GIPANT	PRAYAS PHARMACEUTICALS	40 MG	10	TABLET	25.03	20800	0.00%	0.00%	N	2.50		
44	GLANPAN 40 MG TABLET 10	GLANPAN	GLAND PHARMA LIMITED	40 MG	10	TABLET	38.97	612297	0.01%	0.01%	N	3.90		
45	GOPAN 40 MG TABLET 10	GOPAN	GOLD LINE	40 MG	10	TABLET	60.50	382965	0.00%	0.00%	N	6.05		

